In an unrated note published in a question and answer format on Dec 14, PhillipCapital’s research team spoke to Biolidics on the company’s recent developments on its SARS-CoV-2 Antigen Rapid Test Kit and other Covid-19 test kits. In March 2020, the Singapore-based medical technology company laun...

SHARES in Catalist-listed Biolidics rallied for a third consecutive day on Friday, advancing more than 20 per cent by the closing bell.

SHARES in Catalist-listed Biolidics rallied for a third consecutive day on Friday, advancing more than 20 per cent by the afternoon trade.

THE following companies saw new developments that may affect trading of their securities on Friday.

CATALIST-LISTED medtech firm Biolidics has entered into an agreement with Chinese biotech JOYSBIO (Tianjin) Biotechnology Co to distribute the latter's Covid-19 test kits.

CATALIST-LISTED medtech firm Biolidics on Thursday said its Covid-19 antibody test kits had, on Wednesday, obtained authorisation from the Indonesian health authorities for distribution and use in Indonesia.

CATALIST-LISTED medtech firm Biolidics on Thursday said it has issued a notice of arbitration (NOA) to Japan-based healthcare group Sysmex Corporation in light of disputes over intellectual property (IP).

CATALIST-LISTED medtech firm Biolidics on Thursday said it has issued a notice of arbitration (NOA) to Japan-based healthcare group Sysmex Corporation in light of disputes over intellectual property (IP) matters.

A CATALIST-LISTED medtech firm that made strong gains this year as investors hunted for exposure to tech plays and Covid-19 test makers, has now claimed that a Japanese group breached intellectual property-related (IP) agreements.

BIOLIDICS has issued a letter of demand to Japan-based healthcare group Sysmex Corporation, it said in a bourse filing on Friday.